Medulloblastoma - Pipeline Review, H1 2017

  • ID: 4318731
  • Report
  • 141 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Bayer AG
  • Ignyta Inc
  • IMPACT Therapeutics Inc
  • Lipocure Ltd
  • MacroGenics Inc
  • NewLink Genetics Corp
  • MORE
Medulloblastoma - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Medulloblastoma - Pipeline Review, H1 2017, provides an overview of the Medulloblastoma (Oncology) pipeline landscape.

Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occur in the cerebellum, which is the part of brain located at the base of the skull, just above the brainstem. Symptoms associated with a medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting and difficulty walking and with balance. Medulloblastoma can spread to other areas of the central nervous system. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Medulloblastoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Medulloblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Medulloblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 5, 3 and 13 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Medulloblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Medulloblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Medulloblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Medulloblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Medulloblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Medulloblastoma (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Medulloblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Medulloblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bayer AG
  • Ignyta Inc
  • IMPACT Therapeutics Inc
  • Lipocure Ltd
  • MacroGenics Inc
  • NewLink Genetics Corp
  • MORE
  1. Introduction
  2. Medulloblastoma - Overview
  3. Medulloblastoma - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Medulloblastoma - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Medulloblastoma - Companies Involved in Therapeutics Development
  15. Bayer AG
  16. Bristol-Myers Squibb Company
  17. DelMar Pharmaceuticals Inc
  18. Ignyta Inc
  19. IMPACT Therapeutics Inc
  20. Lipocure Ltd
  21. MacroGenics Inc
  22. NewLink Genetics Corp
  23. Novogen Ltd
  24. Ono Pharmaceutical Co Ltd
  25. Progenics Pharmaceuticals Inc
  26. Stemline Therapeutics Inc
  27. ThromboGenics NV
  28. VBI Vaccines Inc
  29. Medulloblastoma - Drug Profiles
  30. (topotecan hydrochloride + vincristine sulfate) - Drug Profile
  31. Product Description
  32. Mechanism Of Action
  33. R&D Progress
  34. Bispecific Monoclonal Antibodies to Target IL13Ralpha2 and CD3 for Melanoma, Glioblastoma Multiforme and Medulloblastoma - Drug Profile
  35. Product Description
  36. Mechanism Of Action
  37. R&D Progress
  38. Bispecific Monoclonal Antibodies to Target ROR1 and CD3 for Oncology - Drug Profile
  39. Product Description
  40. Mechanism Of Action
  41. R&D Progress
  42. dianhydrogalactitol - Drug Profile
  43. Product Description
  44. Mechanism Of Action
  45. R&D Progress
  46. Edotreotide Labeled Yttrium 90 - Drug Profile
  47. Product Description
  48. Mechanism Of Action
  49. R&D Progress
  50. IMP-5471 - Drug Profile
  51. Product Description
  52. Mechanism Of Action
  53. R&D Progress
  54. indoximod - Drug Profile
  55. Product Description
  56. Mechanism Of Action
  57. R&D Progress
  58. ipilimumab + nivolumab - Drug Profile
  59. Product Description
  60. Mechanism Of Action
  61. R&D Progress
  62. irinotecan hydrochloride + TBio-02 - Drug Profile
  63. Product Description
  64. Mechanism Of Action
  65. R&D Progress
  66. LY-5 - Drug Profile
  67. Product Description
  68. Mechanism Of Action
  69. R&D Progress
  70. nifurtimox - Drug Profile
  71. Product Description
  72. Mechanism Of Action
  73. R&D Progress
  74. nifurtimox SR - Drug Profile
  75. Product Description
  76. Mechanism Of Action
  77. R&D Progress
  78. nivolumab - Drug Profile
  79. R&D Progress
  80. Oncolytic Virus to Target CD46 and SLC5A5 for Brain Tumor and Recurrent Medulloblastoma - Drug Profile
  81. Product Description
  82. Mechanism Of Action
  83. R&D Progress
  84. p28 - Drug Profile
  85. Product Description
  86. Mechanism Of Action
  87. R&D Progress
  88. pyrvinium pamoate - Drug Profile
  89. Product Description
  90. Mechanism Of Action
  91. R&D Progress
  92. SL-301 - Drug Profile
  93. Product Description
  94. Mechanism Of Action
  95. R&D Progress
  96. Small Molecules to Inhibit STAT3 for Medulloblastoma and Glioblastoma Multiforme - Drug Profile
  97. Product Description
  98. Mechanism Of Action
  99. R&D Progress
  100. taladegib - Drug Profile
  101. Product Description
  102. Mechanism Of Action
  103. R&D Progress
  104. THR-317 - Drug Profile
  105. Product Description
  106. Mechanism Of Action
  107. R&D Progress
  108. Trilexium - Drug Profile
  109. Product Description
  110. Mechanism Of Action
  111. R&D Progress
  112. VBI-1901 - Drug Profile
  113. Product Description
  114. Mechanism Of Action
  115. R&D Progress
  116. VIMO-001 - Drug Profile
  117. Product Description
  118. Mechanism Of Action
  119. R&D Progress
  120. VMY-1103 - Drug Profile
  121. Product Description
  122. Mechanism Of Action
  123. R&D Progress
  124. Medulloblastoma - Dormant Projects
  125. Medulloblastoma - Product Development Milestones
  126. Featured News & Press Releases
  127. Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting
  128. Oct 13, 2016: DelMar Pharmaceuticals Announces Upcoming Scientific Conference Presentations
  129. Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe
  130. Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit
  131. Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program
  132. Mar 15, 2016: FDA Grants Second Orphan Designation For VAL-083
  133. Feb 19, 2016: Novogen Patent Covering Trilexium Has Been Proceeded To Grant
  134. Nov 11, 2015: DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising Potential Treatment for Pediatric Brain Tumors
  135. Appendix
  136. Methodology
  137. Coverage
  138. Secondary Research
  139. Primary Research
  140. Expert Panel Validation
  141. Contact Us
  142. Disclaimer
List of Tables
  1. Number of Products under Development for Medulloblastoma, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Companies, H1 2017 (Contd..1), H1
  4. Number of Products under Development by Universities/Institutes, H1
  5. Products under Development by Companies, H1
  6. Products under Development by Companies, H1 2017 (Contd..1), H1
  7. Products under Development by Universities/Institutes, H1
  8. Number of Products by Stage and Target, H1
  9. Number of Products by Stage and Mechanism of Action, H1
  10. Number of Products by Stage and Route of Administration, H1
  11. Number of Products by Stage and Molecule Type, H1
  12. Medulloblastoma - Pipeline by Bayer AG, H1
  13. Medulloblastoma - Pipeline by Bristol-Myers Squibb Company, H1
  14. Medulloblastoma - Pipeline by DelMar Pharmaceuticals Inc, H1
  15. Medulloblastoma - Pipeline by Ignyta Inc, H1
  16. Medulloblastoma - Pipeline by IMPACT Therapeutics Inc, H1
  17. Medulloblastoma - Pipeline by Lipocure Ltd, H1
  18. Medulloblastoma - Pipeline by MacroGenics Inc, H1
  19. Medulloblastoma - Pipeline by NewLink Genetics Corp, H1
  20. Medulloblastoma - Pipeline by Novogen Ltd, H1
  21. Medulloblastoma - Pipeline by Ono Pharmaceutical Co Ltd, H1
  22. Medulloblastoma - Pipeline by Progenics Pharmaceuticals Inc, H1
  23. Medulloblastoma - Pipeline by Stemline Therapeutics Inc, H1
  24. Medulloblastoma - Pipeline by ThromboGenics NV, H1
  25. Medulloblastoma - Pipeline by VBI Vaccines Inc, H1
  26. Medulloblastoma - Dormant Projects, H1
List of Figures
  1. Number of Products under Development for Medulloblastoma, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Number of Products by Top 10 Targets, H1
  5. Number of Products by Stage and Top 10 Targets, H1
  6. Number of Products by Top 10 Mechanism of Actions, H1
  7. Number of Products by Stage and Top 10 Mechanism of Actions, H1
  8. Number of Products by Routes of Administration, H1
  9. Number of Products by Stage and Routes of Administration, H1
  10. Number of Products by Molecule Types, H1
  11. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Bayer AG
  • Bristol-Myers Squibb Company
  • DelMar Pharmaceuticals Inc
  • Ignyta Inc
  • IMPACT Therapeutics Inc
  • Lipocure Ltd
  • MacroGenics Inc
  • NewLink Genetics Corp
  • Novogen Ltd
  • Ono Pharmaceutical Co Ltd
  • Progenics Pharmaceuticals Inc
  • Stemline Therapeutics Inc
  • ThromboGenics NV
  • VBI Vaccines Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll